Trulicity Cost in Kansas 2026: Cash Price, Insurance, Medicaid, and Compounded Dulaglutide Options

What Is the Cash Price of Trulicity in Kansas in 2026?

The cash price for a one-month supply of Trulicity (four 0.75 mg or 1.5 mg single-dose pens) at Kansas retail pharmacies averages $931 in 2026, matching Eli Lilly's manufacturer list price. No meaningful retail discount exists for uninsured patients paying out of pocket without a manufacturer coupon or third-party assistance program.

Trulicity is a GLP-1 receptor agonist (GLP-1 RA) containing dulaglutide, a long-acting glucagon-like peptide-1 analogue. The FDA approved dulaglutide in September 2014 for glycemic control in adults with type 2 diabetes [1]. In 2020, the FDA expanded the label to include reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1]. The REWIND trial (N=9,901, median follow-up 5.4 years) demonstrated a 12% relative risk reduction in MACE with dulaglutide 1.5 mg once weekly compared to placebo (HR 0.88 to 95% CI 0.79, 0.99, P=0.026) [2]. That cardiovascular indication strengthened payer coverage arguments, though Kansas Medicaid has not yet acted on it for the state's formulary.

Retail pharmacy pricing at major Kansas chains, including Walgreens in Wichita, CVS in Overland Park, and HyVee pharmacy locations in Topeka and Lawrence, consistently reflects the $931 list price. GoodRx coupons for dulaglutide in Kansas reduce the cash price modestly, typically to $880, $920 depending on location, but no coupon brings the price below $850 at standard retail outlets [3].

For patients who do not qualify for Medicaid and lack commercial insurance, the $931 monthly price represents a substantial barrier. The sections below cover every legitimate cost-reduction pathway available in Kansas.

Does Kansas Medicaid Cover Trulicity?

Kansas Medicaid (KanCare) does not cover Trulicity for type 2 diabetes on its current preferred drug list. Patients enrolled in KanCare managed care organizations, including Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan of Kansas, face the same exclusion across all three managed care contracts.

The KanCare formulary favors metformin, sulfonylureas, and certain older insulin products for type 2 diabetes as first-line agents. GLP-1 receptor agonists as a class are subject to stringent prior authorization criteria, and dulaglutide specifically does not appear on the KanCare preferred drug list as of July 2025 [4]. Semaglutide (Ozempic) faces a similar restriction. Some GLP-1 RAs may receive coverage for cardiovascular indications if a patient meets specific documented criteria, but no blanket approval exists for dulaglutide under KanCare at this time.

Patients on KanCare who require a GLP-1 RA for documented cardiovascular risk reduction, consistent with the REWIND trial indication, may request a prior authorization exception. The American Diabetes Association 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended" [5]. Citing this guideline in a prior authorization appeal letter, along with REWIND outcome data, gives providers the strongest available clinical argument.

If an appeal fails, patients should document the denial in writing and ask their prescribing clinician about alternative GLP-1 RAs that may have different KanCare formulary status, or consider the 503A compounding pathway described below.

Which Kansas Commercial Insurance Plans Cover Trulicity?

Coverage varies significantly by plan tier, formulary year, and prior authorization requirements. Most Kansas commercial insurers place Trulicity on a non-preferred specialty tier, requiring prior authorization and, in many cases, step therapy through metformin and at least one additional oral agent before approval.

Blue Cross and Blue Shield of Kansas typically places dulaglutide on Tier 3 or Tier 4 of its commercial formularies, requiring prior authorization [6]. Cigna, Aetna, and UnitedHealthcare plans sold in Kansas follow similar tier structures. After prior authorization approval, patient cost-sharing with commercial insurance commonly ranges from $50 to $150 per month depending on deductible status and plan design.

Employer-sponsored plans self-funded under ERISA may have more flexible formulary policies. Kansas state employee health plan participants should check the Kansas Public Employees Retirement System (KPERS) benefit guide for the current plan year, as specialty drug tiers and prior authorization thresholds differ from commercial products.

The key documents to gather for a prior authorization request are: a documented hemoglobin A1c (HbA1c) above the insurer's threshold (often 7.5% or 8.0%), evidence of prior metformin use or a documented contraindication, and the prescribing clinician's clinical rationale [7]. If cardiovascular risk reduction is the primary indication, REWIND data and current ADA guideline language support medical necessity arguments [2][5].

How Does the Eli Lilly Trulicity Savings Card Work in Kansas?

Eligible commercially insured Kansas patients can pay as little as $25 per month for Trulicity through the Eli Lilly Trulicity savings card program. The card is not valid for patients covered by any federal or state government program, including Medicare Part D, Medicaid (KanCare), TRICARE, or the VA.

The savings card works as a secondary payment mechanism at the pharmacy counter. The patient's commercial insurance processes the claim first, and the Lilly savings card covers most or all of the remaining patient cost-share, subject to an annual maximum benefit. As of 2025, Lilly caps the savings card benefit at $150 per month per prescription, making the $25 copay achievable for most commercially insured patients whose plan covers Trulicity at any tier [8].

To activate the card, patients can enroll at LillyInsulin.com or through the Lilly Cares Foundation portal. Kansas pharmacists at major retail chains are familiar with processing the savings card. Patients should confirm their plan's coverage status before relying solely on the savings card, because the card does not pay the full list price of $931 if the insurance plan excludes dulaglutide entirely.

Patients whose commercial plan denies Trulicity entirely and who do not qualify for Medicaid should look at the Lilly Cares Foundation patient assistance program, which provides Trulicity at no cost to patients meeting income and insurance eligibility thresholds [8].

Is Compounded Dulaglutide Legal in Kansas?

Compounded dulaglutide prepared by a Kansas-licensed 503A pharmacy is legal under current federal and Kansas state pharmacy law, provided the pharmacy compounds only for individual patients with a valid prescription from a licensed prescriber. The FDA classifies dulaglutide as a biologic, which creates a distinct legal question compared to small-molecule GLP-1 drugs.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare patient-specific preparations of drugs, including biologics, when a licensed prescriber issues a valid prescription [9]. Kansas Board of Pharmacy rules align with federal 503A requirements. A 503A pharmacy cannot manufacture dulaglutide in bulk without a patient-specific prescription, and it cannot wholesale compounded dulaglutide without additional 503B outsourcing facility registration.

The FDA has not placed dulaglutide on its "biologics not appropriate for compounding" list as of mid-2025, which means 503A compounding remains permitted [9]. This contrasts with the situation for semaglutide, which was removed from the FDA drug shortage list in early 2025, triggering enforcement actions against compounders of that specific molecule. Dulaglutide has not been subject to the same shortage-list removal process as of this article's publication date.

The HealthRX clinical team uses the following decision framework for Kansas patients considering compounded dulaglutide:

1. Confirm the prescribing clinician has issued a valid patient-specific prescription.
2. Verify the dispensing pharmacy holds a current Kansas Board of Pharmacy 503A license and is in good standing.
3. Ask the pharmacy for a Certificate of Analysis from a third-party lab confirming potency, sterility, and absence of endotoxins.
4. Understand that compounded dulaglutide is not FDA-approved and lacks the clinical trial safety and efficacy record of brand-name Trulicity.
5. Monitor HbA1c and GI tolerability the same way one would with branded Trulicity, given that the active peptide sequence is the same.

Compounded dulaglutide from a 503A pharmacy typically costs significantly less than the $931 list price of branded Trulicity. Because pricing is set individually by each compounding pharmacy, patients should call at least two Kansas-licensed 503A pharmacies for quotes. Some telehealth platforms that operate in Kansas bundle the prescription and the compounded medication into a monthly subscription that may reduce total cost substantially.

The FDA has stated: "A compounded drug is not FDA-approved. FDA has not evaluated it for safety, effectiveness, or quality" [9]. Patients should weigh the cost difference against the absence of regulatory manufacturing oversight that applies to brand-name Trulicity.

Can I Get a Trulicity Prescription via Telehealth in Kansas?

Telehealth prescribing of Trulicity is legal in Kansas. Kansas follows standard interstate prescribing rules, and the state is a member of the Interstate Medical Licensure Compact, meaning out-of-state physicians holding a compact license may prescribe controlled and non-controlled medications to Kansas patients via telehealth [10].

Dulaglutide is not a controlled substance, so Schedule II prescribing restrictions do not apply. A clinician licensed in Kansas, or licensed in another state with compact prescribing authority in Kansas, may write a Trulicity prescription after a synchronous audio-video visit or, in some circumstances, an asynchronous evaluation depending on the platform's protocols and Kansas telehealth rules [10].

Telehealth platforms operating in Kansas that specialize in metabolic health and diabetes management, including HealthRX, can evaluate patients for GLP-1 RA therapy, order baseline labs (HbA1c, comprehensive metabolic panel, lipid panel), and issue prescriptions that are sent either to a local Kansas pharmacy or to a partner 503A compounding pharmacy. The typical telehealth visit for initial dulaglutide prescribing takes 20 to 30 minutes and covers cardiovascular history, current medications, kidney function (GFR), and gastrointestinal history.

The ADA 2024 Standards of Care recommend considering GLP-1 RAs in patients with type 2 diabetes and an HbA1c above individualized targets after metformin, particularly when cardiovascular, renal, or weight-related benefits are relevant [5]. Telehealth prescribers in Kansas apply the same clinical threshold.

Patients starting Trulicity via telehealth should expect a 4-week titration at 0.75 mg once weekly before the standard 1.5 mg dose, consistent with the FDA-approved label [1]. Higher doses (3.0 mg and 4.5 mg) are available for additional glycemic lowering if tolerated, as demonstrated in the AWARD-11 trial (N=1,842), which showed HbA1c reductions of 1.8% and 2.0% at 3.0 mg and 4.5 mg respectively versus 1.6% at 1.5 mg at 52 weeks [11].

Understanding Dulaglutide's Clinical Evidence Base

Kansas patients and prescribers making cost-benefit decisions about Trulicity benefit from understanding the drug's core efficacy and safety data. Dulaglutide's efficacy rests on a substantial trial program.

The REWIND trial (N=9,901) is the cornerstone cardiovascular outcomes trial. Published in The Lancet in 2019, it enrolled patients with type 2 diabetes with either established cardiovascular disease or two or more cardiovascular risk factors. Dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint (non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes) by 12% versus placebo over a median 5.4 years (HR 0.88 to 95% CI 0.79, 0.99, P=0.026) [2]. The trial population was notably diverse in cardiovascular risk profile, with approximately 31% having established cardiovascular disease at baseline.

The AWARD trial program established glycemic efficacy. AWARD-1 (N=976) demonstrated that dulaglutide 1.5 mg produced a mean HbA1c reduction of 1.51% from baseline versus 0.99% with exenatide 10 mcg twice daily at 26 weeks [12]. AWARD-5 compared dulaglutide to sitagliptin, showing a 1.1% greater HbA1c reduction with dulaglutide 1.5 mg at 52 weeks in patients on background metformin [13].

Dulaglutide's most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, and abdominal pain. In REWIND, gastrointestinal adverse events led to discontinuation in approximately 1.5% of dulaglutide participants [2]. The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent data; dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Renal dosing adjustment is not required for dulaglutide, a practical advantage over some other diabetes medications. The drug may be used in patients with estimated GFR as low as 15 mL/min/1.73m2, though clinical experience below 30 mL/min is limited [1][14].

What Are the Cheapest Ways to Get Trulicity in Kansas?

Several concrete options exist for reducing the cost of Trulicity or accessing equivalent GLP-1 therapy at lower cost in Kansas. The right path depends on insurance status, income, and clinical eligibility.

Commercially insured patients should activate the Eli Lilly savings card first. The $25/month copay cap is the lowest cost available for branded Trulicity [8]. If the plan excludes Trulicity entirely, the prescriber should file a prior authorization with clinical documentation citing HbA1c, prior therapy, and cardiovascular risk, referencing the ADA 2024 Standards of Care [5] and REWIND outcomes [2].

Uninsured or underinsured patients below 400% of the federal poverty level may qualify for the Lilly Cares Foundation patient assistance program, which provides Trulicity at no charge [8]. Applications require proof of income and a prescriber's signature.

Patients who do not qualify for assistance programs and cannot afford $931/month may discuss compounded dulaglutide with their prescriber. A Kansas-licensed 503A pharmacy compounding patient-specific dulaglutide at a clinician's direction is the most accessible low-cost option outside of manufacturer assistance, though it lacks FDA manufacturing oversight [9].

GoodRx and similar pharmacy discount cards provide marginal reductions at Kansas retail pharmacies, generally $10, $50 below list price [3]. These cards cannot be combined with insurance or the Lilly savings card.

Patients switching from Trulicity to a biosimilar should note that no FDA-approved dulaglutide biosimilar exists as of mid-2025. The dulaglutide patent estate protects the branded product through the late 2020s, meaning biosimilar competition is not an imminent cost-reduction pathway [15].

Dosing, Storage, and Administration Notes for Kansas Patients

Trulicity comes as a single-dose autoinjector pen pre-filled with 0.5 mL of solution. The four available dose strengths are 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Standard starting dose is 0.75 mg once weekly for 4 weeks, then titration to 1.5 mg once weekly [1].

Pens must be stored refrigerated at 36°F to 46°F (2°C to 8°C). They may be kept at room temperature (no higher than 77°F / 25°C) for up to 14 days. Kansas summers routinely reach temperatures above 100°F in Wichita, Dodge City, and other parts of the state; patients must not leave pens in vehicles or unrefrigerated bags during hot months [1].

Injection sites include the abdomen, thigh, or upper arm. The day of the week for injection may be changed as long as the next dose is at least 3 days after the previous dose. The pen does not need to be primed before use [1].

A one-month supply is four pens. Kansas retail pharmacies dispense Trulicity in boxes of four pens (a 28-day supply). Mail-order pharmacies affiliated with commercial insurance plans often allow 90-day supplies (12 pens), which may reduce per-dose cost-sharing under some plan designs [6].